[The use of topiramate at patients with combined craniovertebral anomaly].
Twenty-eight patients with concomitant cranio-vertebral anomaly: Kimmerle anomaly and Chiari type I malformation were examined. A main reason for visiting a doctor was headache, dizziness and sleep disturbance. Topamax (topiramate) was used for stopping the symptoms. It was prescribed in dosage 25 mg in the evening to 16 patients and in dosage 25 mg in the first two weeks and then in dosage 50 mg in the evening for 60 days - to 12 patients. The use of Topamax led to the reduction and /or disappearance of headache, sleep normalization and improvement of cerebral bioelectric activity. The drug was well tolerated.
Klocheva
E G
EG
Komiakhov
A V
AV
Zhukova
M V
MV
D000015:Abnormalities, Multiple / Q000188:drug therapy*; D000328:Adult; D001270:Cervical Atlas / Q000002:abnormalities*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D005632:Fructose / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D020773:Headache Disorders / Q000151:congenital / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D012886:Skull / Q000002:abnormalities*; D012890:Sleep / Q000187:drug effects; D000077236:Topiramate; D016896:Treatment Outcome; D055815:Young Adult
D018696:Neuroprotective Agents; D000077236:Topiramate; D005632:Fructose